The AK-OTOF therapy remains in early-stage clinical testing, but the success in the first patient to receive it – an 11-year-old boy who was profoundly deaf, but whose hearing is now reported to ...
The preliminary results from the Audiogene study, conducted in children aged six to 31 months without cochlear hearing implants, also showed that the SENS-501 (formerly OTOF-GT) gene therapy was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback